Novartis Ag (NVS) Revenue Growth (5y) (2014 - 2024)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -16.90% |
| Dec 31, 2023 | 149.93% |
| Jun 30, 2023 | -0.96% |
| Mar 31, 2023 | 8.85% |
| Dec 31, 2022 | 4.69% |
| Sep 30, 2022 | 4.21% |
| Jun 30, 2022 | 164.65% |
| Dec 31, 2021 | -2.69% |
| Sep 30, 2021 | 3.86% |
| Jun 30, 2021 | 175.17% |
| Mar 31, 2021 | 1,615.73% |
| Dec 31, 2020 | 30.07% |
| Sep 30, 2020 | 27,635.87% |
| Mar 31, 2020 | 1,639.65% |
| Mar 31, 2019 | 1,851.63% |
| Dec 31, 2015 | 8,453.25% |
| Mar 31, 2015 | -99.83% |
| Dec 31, 2014 | -63.22% |
| Sep 30, 2014 | -99.85% |
| Mar 31, 2014 | -61.42% |